NAD+ supplementation improves cardiomyocyte resilience to doxorubicin-induced cardiotoxicity
The number of cancer survivors has markedly increased in recent years, bringing greater attention to cancer therapy-related therapy related to cardiac dysfunction (CTRCD). Anthracyclines, such as doxorubicin (DOXO), are widely used chemotherapeutics but are well known to induce oxidative stress, mitochondrial dys...